Top-News

Sarossa Capital News

Keine aktuellen Kursdaten verfügbar
WKN: A110TL
ISIN: JE00BKWBZV64
US-Symbol: AIOAF
Typ: Aktie

Sarossa Capital News

31.01.11 - Hugin
Antisoma reports outcome of AS1413 phase III trial
London, UK, and Cambridge, MA: 31 January 2011 - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the ACCEDE phase III trial of AS1413 (amonafide) in secondary acute ...
02.12.10 - Hugin
Antisoma ASH meeting update
London, UK, and Cambridge, MA: 2 December 2010 - Antisoma plc (LSE: ASM; USOTC: ATSMY) today provides an update on its blood cancer programmes and announces details ...
30.11.10 - Hugin
AS1413 phase III AML data now expected Q1 2011
London, UK, and Cambridge, MA: 30 November 2010 - During its presentation today at the Piper Jaffray conference, Antisoma plc (LSE: ASM; USOTC: ATSMY) will announce that it ...
24.11.10 - Hugin
Antisoma to present at Piper Jaffray Health Care Conference on Tuesday, November 30
24 November 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive Officer, Glyn Edwards, will present at the Piper ...
11.11.10 - Hugin
Antisoma announces outcome of ASA404 ATTRACT-2 trial
11 November 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that a scheduled interim analysis showed that the ATTRACT-2 trial ...
08.11.10 - Hugin
Antisoma awarded US Qualifying Therapeutic Discovery Project grant of USD 244K
London, UK, and Cambridge, MA: 8 November 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that the Company's US subsidiary, ...
13.10.10 - Hugin
Antisoma Interim Management Statement
London, UK, and Cambridge, MA: 13 October 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement for the ...
08.09.10 - Hugin
Antisoma's phase III trial of AS1413 completes patient enrolment
London, UK, and Cambridge, MA: 8 September 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the ACCEDE phase III trial of AS1413 ...
02.09.10 - Hugin
Antisoma Annual Report and Accounts 2010
02 September 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Annual Report and Accounts for the year ended 30 June 2010 ...
06.08.10 - Hugin
Antisoma to present at Canaccord Global Growth Conference
6 August 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that senior executive Dr Michael Boss will present at the 30th Annual ...
29.07.10 - Hugin
Antisoma's preliminary results for the year ended 30 June 2010
London, UK, and Cambridge, MA: 29 July 2010 Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces its preliminary results for the year ended 30 June 2010. These results ...
21.06.10 - Hugin
Antisoma to present at 5th Annual Piper Jaffray Europe Healthcare Conference
21 June 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its CEO, Glyn Edwards, will present at the 5(th) Annual Piper Jaffray ...
14.06.10 - Hugin
Antisoma announces AS1413 and AS1411 presentations at EHA
London, UK, Cambridge, MA, and Barcelona, Spain: 14 June 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that five presentations, including ...
05.06.10 - Hugin
Antisoma announces presentation at ASCO of new data supporting AS1413 and AS1411
London, UK, Cambridge, MA, and Chicago, IL: 5 June 2010 - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces the presentation of new data supporting AS1413 and AS1411 at ...
04.06.10 - Hugin
Antisoma to present at 9th Annual Needham Life Sciences Conference and 4th Annual Jefferies Healthcare Conference in New York
04 June 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present at the 9th ...
03.06.10 - Hugin
Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia
London, UK, and Cambridge, MA: 3 June 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that the U.S. Food and Drug Administration ...
21.05.10 - Hugin
Antisoma to present at the Citi Investment Research Global Health Care Conference
21 May 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its CEO, Glyn Edwards, will present at the 2010 Citi Investment Research ...
17.05.10 - Hugin
Antisoma Interim Management Statement
London, UK, and Cambridge, MA: 17 May 2010 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement for the period ...
13.05.10 - Hugin
Antisoma to present at the Rodman and Renshaw Annual Global Investment Conference
13 May 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present an overview of ...
19.04.10 - Hugin
AACR presentations highlight potential of Antisoma drugs AS1413 and AS1411
London, UK, Cambridge, MA, and Washington, DC: 19 April 2010 - Antisoma plc (LSE:ASM; USOTC:ATSMY) announces that its scientists and collaborators are presenting six ...

Newssuche

Videos

newspaper
09:10 Uhr
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »